Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Olema Pharmaceuticals, Inc.OLMA · Entity 613 | Director | July 23, 2026 | July 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Olema Pharmaceuticals, Inc.
Report date July 23, 2026 · Filed July 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 702,770 |
Ending reported balance
After 2026-07-24 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-23 · Sale · Disposed 12,500 · Balance 715,270 F1: The weighted average sale price for the transaction reported was $11.579, and the range of prices were between $11.52 and $11.675. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Row 2 · 2026-07-24 · Sale · Disposed 12,500 · Balance 702,770 F2: The weighted average sale price for the transaction reported was $11.714, and the range of prices were between $11.70 and $11.775. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 117,028 |
Reported balance
Holding disclosure · report date 2026-07-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 117,028 F3: The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager. |
Filing footnotes · ownership attribution and instrument terms
F1: The weighted average sale price for the transaction reported was $11.579, and the range of prices were between $11.52 and $11.675. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F2: The weighted average sale price for the transaction reported was $11.714, and the range of prices were between $11.70 and $11.775. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F3: The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 24, 2026 Filed Jul 27, 2026 23:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 12,500 | $11.71 | $146,425.00 |
DisclosureSEC source: 0001831410-26-000008 · form4-07272026_070701.xml · nonDerivative · entry 2 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 702,770 F2 · price: The weighted average sale price for the transaction reported was $11.714, and the range of prices were between $11.70 and $11.775. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| July 23, 2026 Filed Jul 27, 2026 23:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 12,500 | $11.58 | $144,737.50 |
DisclosureSEC source: 0001831410-26-000008 · form4-07272026_070701.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 715,270 F1 · price: The weighted average sale price for the transaction reported was $11.579, and the range of prices were between $11.52 and $11.675. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 29,500 | $0.00 Strike: $9.51 | $0.00 |
DisclosureSEC source: 0001831410-26-000006 · form4-06232026_090619.xml · derivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,500 Underlying: Common Stock · 29,500 shares Expires 2036-06-18 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 02:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 10,000 | $26.88 | $268,800.00 |
DisclosureSEC source: 0001831410-26-000004 · form4-01212026_090101.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 727,770 F1 · price: 2. The weighted average sale price for the transaction reported was $26.88, and the range of prices were between $26.85 and $26.96. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| January 14, 2026 Filed Jan 17, 2026 02:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 3,489 | $29.12 | $101,599.68 |
DisclosureSEC source: 0001831410-26-000002 · form4-01162026_090101.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 737,770 F1 · price: The weighted average sale price for the transaction reported was $29.12, and the range of prices were between $29.00 and $29.23. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 22, 2025 Filed Dec 30, 2025 02:55 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 2,881 | $28.53 | $82,194.93 |
DisclosureSEC source: 0001831410-25-000007 · form4-12292025_091201.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 741,259 F1 · price: The weighted average sale price for the transaction reported was $28.53, and the range of prices was between $28.50 and $28.53. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 18, 2025 Filed Sep 19, 2025 01:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 3,086 | $8.32 | $25,675.52 |
DisclosureSEC source: 0001831410-25-000004 · form4-09182025_090901.xml · nonDerivative · entry 4 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 117,028 F5 · price: The weighted average sale price for the transaction reported was $8.32, and the range of prices was between $8.29 and $8.33. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. F4 · ownership.nature: The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager. Read SEC document |
| September 18, 2025 Filed Sep 19, 2025 01:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 10,000 | $8.33 | $83,300.00 |
DisclosureSEC source: 0001831410-25-000004 · form4-09182025_090901.xml · nonDerivative · entry 2 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 744,140 F2 · price: The weighted average sale price for the transaction reported was $8.33, and the range of prices was between $8.28 and $8.37. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 16, 2025 Filed Sep 19, 2025 01:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 1,914 | $8.08 | $15,465.12 |
DisclosureSEC source: 0001831410-25-000004 · form4-09182025_090901.xml · nonDerivative · entry 3 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 120,114 F3 · price: The weighted average sale price for the transaction reported was $8.08, and the range of prices was between $8.04 and $8.08. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. F4 · ownership.nature: The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager. Read SEC document |
| September 16, 2025 Filed Sep 19, 2025 01:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 10,000 | $8.04 | $80,400.00 |
DisclosureSEC source: 0001831410-25-000004 · form4-09182025_090901.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 754,140 F1 · price: The weighted average sale price for the transaction reported was $8.04, and the range of prices was between $8.02 and $8.09. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 21:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (right to buy) · Derivative | 24,150 | $0.00 Strike: $4.08 | $0.00 |
DisclosureSEC source: 0001415889-25-017234 · form4-06132025_050615.xml · derivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,150 Underlying: Common Stock · 24,150 shares Expires 2035-06-11 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| December 11, 2024 Filed Dec 12, 2024 00:56 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 179 | $9.39 | $1,680.81 |
DisclosureSEC source: 0001415889-24-029028 · form4-12122024_121240.xml · nonDerivative · entry 4 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 764,140 F2 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F5 · price: The weighted average sale price for the transaction reported was $9.39, and the range of prices was between $9.31 and $9.74. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 11, 2024 Filed Dec 12, 2024 00:56 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 7,958 | $8.66 | $68,916.28 |
DisclosureSEC source: 0001415889-24-029028 · form4-12122024_121240.xml · nonDerivative · entry 3 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 764,319 F2 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F4 · price: The weighted average sale price for the transaction reported was $8.66, and the range of prices was between $8.22 and $9.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 00:56 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 8,256 | $9.37 | $77,358.72 |
DisclosureSEC source: 0001415889-24-029028 · form4-12122024_121240.xml · nonDerivative · entry 2 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 772,277 F2 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F3 · price: The weighted average sale price for the transaction reported was $9.37, and the range of prices was between $8.89 and $9.70. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 09, 2024 Filed Dec 12, 2024 00:56 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantCommon Stock | 29,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029028 · form4-12122024_121240.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 780,533 F1 · shares: On November 11, 2022, the Reporting Person was granted certain performance restricted stock units ("PRSUs") for 45,000 shares, which were subject to vesting upon certification by the Compensation Committee of the Company's achievement of two different performance milestones. 35% of the award previously vested on November 20, 2023. On December 9, 2024, the Compensation Committee certified that the remaining 65% of the award vested based on achievement of certain performance criteria. Read SEC document |
| July 30, 2024 Filed Jul 31, 2024 21:15 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 934 | $15.55 | $14,523.70 |
DisclosureSEC source: 0001415889-24-020461 · form4-07312024_050701.xml · nonDerivative · entry 2 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 751,283 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023. F3 · price: The weighted average sale price for the transaction reported was $15.55, and the range of prices was between $15.55 and $15.58. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 21:15 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 4,066 | $15.58 | $63,348.28 |
DisclosureSEC source: 0001415889-24-020461 · form4-07312024_050701.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 752,217 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023. F2 · price: The weighted average sale price for the transaction reported was $15.58, and the range of prices was between $15.55 and $15.64. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| July 11, 2024 Filed Jul 12, 2024 21:15 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 5,000 | $12.26 | $61,300.00 |
DisclosureSEC source: 0001415889-24-019528 · form4-07122024_050702.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 756,283 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023. F2 · price: The weighted average sale price for the transaction reported was $12.26, and the range of prices was between $12.23 and $12.33. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 21:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 20,000 | $10.77 | $215,400.00 |
DisclosureSEC source: 0001415889-24-018975 · form4-07022024_050720.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 761,283 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023. F2 · price: The weighted average sale price for the transaction reported was $10.77, and the range of prices was between $10.55 and $11.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 21:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 23,000 | $0.00 Strike: $12.36 | $0.00 |
DisclosureSEC source: 0001415889-24-017443 · form4-06182024_050609.xml · derivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2034-06-14 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 14, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 04, 2024 Filed Jun 5, 2024 01:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 5,000 | $12.33 | $61,650.00 |
DisclosureSEC source: 0001415889-24-015508 · form4-06042024_090601.xml · nonDerivative · entry 3 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 781,283 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023. F4 · price: The weighted average sale price for the transaction reported was $12.33, and the range of prices was between $12.23 and $12.43. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 01:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 5,000 | $10.93 | $54,650.00 |
DisclosureSEC source: 0001415889-24-015508 · form4-06042024_090601.xml · nonDerivative · entry 2 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 786,283 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023. F3 · price: The weighted average sale price for the transaction reported was $10.93, and the range of prices was between $10.91 and $11.01. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 31, 2024 Filed Jun 5, 2024 01:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 15,000 | $9.41 | $141,150.00 |
DisclosureSEC source: 0001415889-24-015508 · form4-06042024_090601.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 791,283 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023. F2 · price: The weighted average sale price for the transaction reported was $9.41, and the range of prices was between $9.34 and $9.56. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 06, 2024 Filed May 7, 2024 21:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 5,000 | $10.92 | $54,600.00 |
DisclosureSEC source: 0001415889-24-012485 · form4-05072024_050502.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 806,283 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023. F2 · price: The weighted average sale price for the transaction reported was $10.92, and the range of prices was between $10.91 and $10.95. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 30, 2024 Filed May 2, 2024 21:09 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 15,000 | $9.51 | $142,650.00 |
DisclosureSEC source: 0001415889-24-012020 · form4-05022024_090504.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 811,283 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023. F2 · price: The weighted average sale price for the transaction reported was $9.51, and the range of prices was between $9.20 and $9.91. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 28, 2024 Filed Mar 29, 2024 21:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 20,000 | $10.97 | $219,400.00 |
DisclosureSEC source: 0001415889-24-009445 · form4-03292024_050302.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 826,283 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023. F2 · price: The weighted average sale price for the transaction reported was $10.97, and the range of prices was between $10.80 and $11.20. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 22:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 100 | $13.00 | $1,300.00 |
DisclosureSEC source: 0001415889-24-006322 · form4-03042024_050305.xml · nonDerivative · entry 2 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 846,283 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023. F3 · price: The weighted average sale price for the transaction reported was $13.00, and the range of prices was between $12.97 and $13.01. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 22:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 24,900 | $12.41 | $309,009.00 |
DisclosureSEC source: 0001415889-24-006322 · form4-03042024_050305.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 846,383 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023. F2 · price: The weighted average sale price for the transaction reported was $12.41, and the range of prices was between $11.94 and $12.86. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 22:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 5,000 | $15.56 | $77,800.00 |
DisclosureSEC source: 0001415889-24-002350 · form4-02022024_050201.xml · nonDerivative · entry 2 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 871,283 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023. F3 · price: The weighted average sale price for the transaction reported was $15.56, and the range of prices was between $15.55 and $15.59. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 22:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 25,000 | $12.23 | $305,750.00 |
DisclosureSEC source: 0001415889-24-002350 · form4-02022024_050201.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 876,283 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023. F2 · price: The weighted average sale price for the transaction reported was $12.23, and the range of prices was between $12.03 and $12.38. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 29, 2023 Filed Jan 2, 2024 22:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 2,500 | $14.10 | $35,250.00 |
DisclosureSEC source: 0001415889-24-000070 · form4-01022024_050101.xml · nonDerivative · entry 2 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 901,283 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023. F3 · price: The weighted average sale price for the transaction reported was $14.10, and the range of prices was between $14.08 and $14.27. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 29, 2023 Filed Jan 2, 2024 22:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 22,500 | $13.30 | $299,250.00 |
DisclosureSEC source: 0001415889-24-000070 · form4-01022024_050101.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 903,783 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023. F2 · price: The weighted average sale price for the transaction reported was $13.30, and the range of prices was between $13.15 and $13.87. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| November 30, 2023 Filed Dec 1, 2023 22:15 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 25,000 | $12.57 | $314,250.00 |
DisclosureSEC source: 0001415889-23-015701 · form4-12012023_051201.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 926,283 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023. F2 · price: The weighted average sale price for the transaction reported was $12.57, and the range of prices was between $12.30 and $13.02. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| November 22, 2023 Filed Nov 23, 2023 00:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 3,989 | $13.90 | $55,447.10 |
DisclosureSEC source: 0001415889-23-015457 · form4-11222023_071105.xml · nonDerivative · entry 3 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 951,283 F2 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F4 · price: The weighted average sale price for the transaction reported was $13.90, and the range of prices was between $13.62 and $14.14. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| November 21, 2023 Filed Nov 23, 2023 00:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 4,192 | $14.86 | $62,293.12 |
DisclosureSEC source: 0001415889-23-015457 · form4-11222023_071105.xml · nonDerivative · entry 2 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 955,272 F2 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F3 · price: The weighted average sale price for the transaction reported was $14.86, and the range of prices was between $14.26 and $15.19. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| November 20, 2023 Filed Nov 23, 2023 00:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantCommon Stock | 15,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-015457 · form4-11222023_071105.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 959,464 F1 · shares: On November 11, 2022, the Reporting Person was granted certain performance restricted stock units ("PRSUs") for 45,000 shares, which are subject to vesting upon certification by the Compensation Committee of the Company's achieving two different performance milestones. The Compensation Committee certified on November 20, 2023 that 35% of the award vested based upon the certification by the Compensation Committee as to certain performance criteria. Read SEC document |
| November 02, 2023 Filed Nov 3, 2023 00:50 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 5,000 | $15.64 | $78,200.00 |
DisclosureSEC source: 0001415889-23-014714 · form4-11032023_121146.xml · nonDerivative · entry 2 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 943,714 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023. F3 · price: The weighted average sale price for the transaction reported was $15.64, and the range of prices were between $15.55 and $15.75. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| October 31, 2023 Filed Nov 3, 2023 00:50 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 25,000 | $12.05 | $301,250.00 |
DisclosureSEC source: 0001415889-23-014714 · form4-11032023_121146.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 948,714 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023. F2 · price: The weighted average sale price for the transaction reported was $12.05, and the range of prices were between $11.19 and $13.24. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 21:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 25,000 | $12.41 | $310,250.00 |
DisclosureSEC source: 0001415889-23-013898 · form4-10032023_051008.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 973,714 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023. F2 · price: The weighted average sale price for the transaction reported was $12.41, and the range of prices were between $11.86 and $13.18. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 01:08 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 10,000 | $11.62 | $116,200.00 |
DisclosureSEC source: 0001415889-23-012922 · form4-09062023_010901.xml · nonDerivative · entry 2 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 998,714 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023. F3 · price: The weighted average sale price for the transaction reported was $11.62, and the range of prices were between $10.91 and $12.34. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| August 31, 2023 Filed Sep 6, 2023 01:08 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 15,000 | $9.36 | $140,400.00 |
DisclosureSEC source: 0001415889-23-012922 · form4-09062023_010901.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,008,714 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023. F2 · price: The weighted average sale price for the transaction reported was $9.36, and the range of prices were between $9.22 and $9.60. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| August 16, 2023 Filed Aug 17, 2023 21:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 15,000 | $10.14 | $152,100.00 |
DisclosureSEC source: 0001415889-23-012360 · form4-08172023_050801.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,023,714 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023. F2 · price: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023. Read SEC document |
| August 16, 2023 Filed Sep 5, 2023 20:05 UTC Amendment | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 15,000 | $10.14 | $152,100.00 |
DisclosureSEC source: 0001415889-23-012898 · form4a-09052023_040904.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,023,714 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023. F2 · price: On August 17, 2023, the reporting person filed a Form 4 that inadvertently excluded the weighted average sale price for the transaction. This amendment is being filed solely to report that the weighted average sale price for the transaction reported was $10.14, and the range of prices were between $9.765 and $10.65. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 21:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 10,000 | $6.30 | $63,000.00 |
DisclosureSEC source: 0001415889-23-009522 · form4-06092023_050601.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,038,714 F1 · price: The weighted average sale price for the transaction reported was $6.30, and the range of prices were between $6.30 and $6.32. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 01:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 5,000 | $6.30 | $31,475.00 |
DisclosureSEC source: 0001415889-23-009406 · form4-06072023_090601.xml · nonDerivative · entry 2 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,048,714 F3 · price: The weighted average sale price for the transaction reported was $6.295, and the range of prices were between $6.24 and $6.37. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 05, 2023 Filed Jun 8, 2023 01:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 5,000 | $6.05 | $30,225.00 |
DisclosureSEC source: 0001415889-23-009406 · form4-06072023_090601.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,053,714 F1 · price: The weighted average sale price for the transaction reported was $6.045 and the range of prices were between $5.96 and $6.10. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. F2 · balance_after: Includes 7,568 shares acquired under the issuer's Employee Stock Purchase Plan. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 22:23 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $4.87 | $0.00 |
DisclosureSEC source: 0001209191-23-006279 · doc4.xml · derivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:10 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 104,500 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0001415889-22-001059 · form4-02032022_040230.xml · derivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,500 Underlying: Common Stock · 104,500 shares Expires 2032-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 22:34 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 400 | $24.76 | $9,904.00 |
DisclosureSEC source: 0001415889-21-005622 · form4-12012021_021248.xml · nonDerivative · entry 1 Harmon Cyrus · CIK 0001831410 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,051,146 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: The weighted average sale price for the transaction reported was $24.76, and the range of prices were between $24.75 and $24.80. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| October 19, 2021 Filed Oct 21, 2021 20:33 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 4,555 | $28.20 | $128,451.00 |
DisclosureSEC source: 0001415889-21-004934 · form4-10212021_011011.xml · nonDerivative · entry 2 Harmon Cyrus · CIK 0001831410 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,051,546 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · price: The weighted average sale price for the transaction reported was $28.20, and the range of prices were between $28.00 and $28.63. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.